全国性队列研究:感染性心内膜炎二尖瓣修复与置换的比较
基于台湾全民健康保险研究数据库2000至2013年1999例因感染性心内膜炎行二尖瓣手术的患者,经1:1倾向评分匹配后每组352例,比较二尖瓣修复与置换的围术期结局和远期复合终点。修复组围术期并发症更少、院内死亡率更低(6.3% vs 10.8%;P = .031),远期死亡风险(HR 0.59;95%CI 0.44-0.80)和复合终点风险(HR 0.67;95%CI 0.52-0.87)更低。
要点
- 匹配后二尖瓣修复组院内死亡率6.3% vs 置换组10.8%(P = .031)。
- 修复组远期死亡风险HR 0.59(95%CI 0.44-0.80)。
- 修复组远期复合终点风险HR 0.67(95%CI 0.52-0.87)。
核心结论
- 感染性心内膜炎二尖瓣修复的围术期和远期结局优于二尖瓣置换。
- 作者推荐由经验丰富的团队在可能情况下对感染性心内膜炎患者行二尖瓣修复而非置换,即使处于活动性感染状态。
研究设计与样本
- 基于台湾全民健康保险研究数据库的全国性队列研究,纳入2000至2013年因感染性心内膜炎行二尖瓣手术的1999例患者。
- 二尖瓣置换1575例(78.8%),二尖瓣修复424例(21.2%);经1:1倾向评分匹配后每组352例。
- 比较围术期结局和远期复合终点(全因死亡、二尖瓣再手术、任何卒中、大出血、心力衰竭再入院)。
主要发现
- 二尖瓣修复组围术期并发症更少。
- 二尖瓣修复组院内死亡率6.3% vs 置换组10.8%(P = .031)。
- 平均随访4.8年,修复组远期死亡风险HR 0.59(95%CI 0.44-0.80),复合终点风险HR 0.67(95%CI 0.52-0.87)。
- 亚组分析显示,在手术量最低四分位医院手术时修复的获益趋势不明显(交互作用P = .091)。
- 活动性感染期间手术的患者中,二尖瓣修复与较低的远期死亡率相关(HR 0.64;95%CI 0.48-0.85)。
临床怎么用
- 作者推荐由经验丰富的团队在可能情况下对感染性心内膜炎患者行二尖瓣修复而非置换,即使处于活动性感染状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The feasibility and long-term outcomes of mitral valve (MV) repair in patients with infective endocarditis (IE) remain unclear. METHODS: Using Taiwan's National Health Insurance Research Database, we identified 1999 patients who underwent MV surgery for IE during 2000 to 2013. The patients were more likely to have undergone valve replacement (1575 patients; 78.8%) than valve repair (424 patients; 21.2%). After 1:1 propensity score matching, 352 patients in each group were included for analysis. Perioperative outcomes and late composite end points, comprising all-cause mortality, MV reoperation, any stroke, major bleeding, and readmission for heart failure, were compared. RESULTS: Patients who received MV repair had fewer perioperative complications, lower in-hospital mortality rates (6.3% vs 10.8%; P = .031), and lower risks of late mortality (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.44-0.80), and composite end point (HR, 0.67; 95% CI, 0.52-0.87) during a mean follow-up of 4.8 years. Subgroup analysis revealed a trend in which the beneficial effect of MV repair was not apparent when surgeries were performed in hospitals within the lowest volume quartile (P for interaction = .091). In patients who underwent surgery during active IE, MV repair was also related to a lower rate of late mortality (HR, 0.64; 95% CI, 0.48-0.85). CONCLUSIONS: Mitral repair for IE has better perioperative and late outcomes than mitral replacement. Mitral repair performed by an experienced team is recommended for IE patients instead of MV replacement whenever possible, even with an active infection status.
引用
- Lee HA, Cheng YT, Wu VC, et al. Nationwide cohort study of mitral valve repair versus replacement for infective endocarditis. J Thorac Cardiovasc Surg. 2018. PMID: 29843917. doi:10.1016/j.jtcvs.2018.04.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。